Generalized chest CT and lab curves throughout the course of COVID-19.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
25 03 2021
Historique:
received: 09 10 2020
accepted: 03 03 2021
entrez: 26 3 2021
pubmed: 27 3 2021
medline: 15 4 2021
Statut: epublish

Résumé

A better understanding of temporal relationships between chest CT and labs may provide a reference for disease severity over the disease course. Generalized curves of lung opacity volume and density over time can be used as standardized references from well before symptoms develop to over a month after recovery, when residual lung opacities remain. 739 patients with COVID-19 underwent CT and RT-PCR in an outbreak setting between January 21st and April 12th, 2020. 29 of 739 patients had serial exams (121 CTs and 279 laboratory measurements) over 50 ± 16 days, with an average of 4.2 sequential CTs each. Sequential volumes of total lung, overall opacity and opacity subtypes (ground glass opacity [GGO] and consolidation) were extracted using deep learning and manual segmentation. Generalized temporal curves of CT and laboratory measurements were correlated. Lung opacities appeared 3.4 ± 2.2 days prior to symptom onset. Opacity peaked 1 day after symptom onset. GGO onset was earlier and resolved later than consolidation. Lactate dehydrogenase, and C-reactive protein peaked earlier than procalcitonin and leukopenia. The temporal relationships of quantitative CT features and clinical labs have distinctive patterns and peaks in relation to symptom onset, which may inform early clinical course in patients with mild COVID-19 pneumonia, or may shed light upon chronic lung effects or mechanisms of medical countermeasures in clinical trials.

Identifiants

pubmed: 33767213
doi: 10.1038/s41598-021-85694-5
pii: 10.1038/s41598-021-85694-5
pmc: PMC7994835
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

6940

Subventions

Organisme : NCI NIH HHS
ID : 75N91019D00024
Pays : United States
Organisme : Intramural NIH HHS
ID : ZID BC011242
Pays : United States
Organisme : National Institutes of Health, Center for Interventional Oncology
ID : Z01 1ZID BC011242

Références

Eur Radiol. 2020 Nov;30(11):6194-6203
pubmed: 32524223
Eur Radiol. 2016 Dec;26(12):4465-4474
pubmed: 27048527
Theranostics. 2020 Apr 27;10(12):5641-5648
pubmed: 32373237
Radiology. 2016 Sep;280(3):931-9
pubmed: 27097236
Korean J Radiol. 2020 Jul;21(7):859-868
pubmed: 32524786
AJR Am J Roentgenol. 2000 Nov;175(5):1329-34
pubmed: 11044035
Radiology. 2020 Jun;295(3):200463
pubmed: 32077789
PLoS One. 2018 Oct 18;13(10):e0205490
pubmed: 30335856
Theranostics. 2020 Apr 27;10(12):5613-5622
pubmed: 32373235
Eur Radiol. 2020 Aug;30(8):4407-4416
pubmed: 32215691
Ann Intern Med. 2020 Aug 18;173(4):262-267
pubmed: 32422057
Radiology. 2020 Aug;296(2):E55-E64
pubmed: 32191587
Eur J Radiol. 2020 Sep;130:109202
pubmed: 32745895
Radiology. 2020 Jun;295(3):715-721
pubmed: 32053470
Radiology. 2020 Jul;296(1):172-180
pubmed: 32255413
Lancet. 2020 Apr 11;395(10231):1189-1190
pubmed: 32224299
Eur J Cardiothorac Surg. 2004 Jun;25(6):1102-6
pubmed: 15145016
Radiology. 2020 Apr;295(1):202-207
pubmed: 32017661
Eur Radiol. 2020 Dec;30(12):6770-6778
pubmed: 32591888
Sci Rep. 2020 Jul 9;10(1):11336
pubmed: 32647307
Int J Infect Dis. 2020 Jul;96:157-162
pubmed: 32423888
Med Image Comput Comput Assist Interv. 2005;8(Pt 1):851-8
pubmed: 16685926
Chin J Acad Radiol. 2020;3(2):102-107
pubmed: 32395696
Eur J Radiol. 2020 Jun;127:109009
pubmed: 32325282
Radiology. 2020 Aug;296(2):E86-E96
pubmed: 32301647
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Radiol Cardiothorac Imaging. 2020 Mar 30;2(2):e200075
pubmed: 33778562
Invest Radiol. 2020 Jul;55(7):412-421
pubmed: 32304402
JAMA. 2020 Jun 9;323(22):2249-2251
pubmed: 32374370
Radiology. 2021 Feb;298(2):E63-E69
pubmed: 32729811
Radiol Infect Dis. 2020 Jun;7(2):55-61
pubmed: 32346594

Auteurs

Michael T Kassin (MT)

Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center and National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Radiology and Imaging Sciences, NIH Clinical Center, National Institutes of Health, Bethesda, MD, 20892-1182, USA.

Nicole Varble (N)

Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center and National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Philips Research North America, Cambridge, MA, 02141, USA.

Maxime Blain (M)

Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center and National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

Sheng Xu (S)

Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center and National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

Evrim B Turkbey (EB)

Radiology and Imaging Sciences, NIH Clinical Center, National Institutes of Health, Bethesda, MD, 20892-1182, USA.

Stephanie Harmon (S)

National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Clinical Research Directorate, Frederick National Laboratory for Cancer Research, NCI, Frederick, MD, 21702, USA.
Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

Dong Yang (D)

NVIDIA Corporation, Bethesda, MD, 20892, USA.

Ziyue Xu (Z)

NVIDIA Corporation, Bethesda, MD, 20892, USA.

Holger Roth (H)

NVIDIA Corporation, Bethesda, MD, 20892, USA.

Daguang Xu (D)

NVIDIA Corporation, Bethesda, MD, 20892, USA.

Mona Flores (M)

NVIDIA Corporation, Santa Clara, CA, 95051, USA.

Amel Amalou (A)

Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center and National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

Kaiyun Sun (K)

Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, MD, 20892, USA.

Sameer Kadri (S)

Critical Care Medicine Department, NIH Clinical Center, National Institutes of Health, Bethesda, MD, 20892, USA.

Francesca Patella (F)

Diagnostic and Interventional Radiology Service, ASST Santi Paolo e Carlo, Milan, Italy.

Maurizio Cariati (M)

Diagnostic and Interventional Radiology Service, ASST Santi Paolo e Carlo, Milan, Italy.

Alice Scarabelli (A)

Postgraduate School of Diagnostic and Interventional Radiology, University of Milan, Milan, Italy.

Elvira Stellato (E)

Postgraduate School of Diagnostic and Interventional Radiology, University of Milan, Milan, Italy.

Anna Maria Ierardi (AM)

Department of Radiology and Department of Health Sciences, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico and University of Milano, 20122, Milan, Italy.

Gianpaolo Carrafiello (G)

Department of Radiology and Department of Health Sciences, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico and University of Milano, 20122, Milan, Italy.

Peng An (P)

Department of Radiology, Xiangyang NO. 1 People's Hospital Affiliated to Hubei University of Medicine, Xiangyang, Hubei, 441000, China.

Baris Turkbey (B)

National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

Bradford J Wood (BJ)

Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center and National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA. bwood@nih.gov.
Radiology and Imaging Sciences, NIH Clinical Center, National Institutes of Health, Bethesda, MD, 20892-1182, USA. bwood@nih.gov.
National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA. bwood@nih.gov.
National Institute of Biomedical Imaging and Bioengineering, Bethesda, MD, 20892, USA. bwood@nih.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH